Green Park Pharma secures £2.2m pre-series A funding to advance liquid medication technology
The pre-series A round was backed by The FSE Group through the South West Investment Fund.
Green Park Pharma develops patented, stable liquid formulations of existing medications to help patients who struggle with swallowing traditional tablets.
Green Park Pharma has secured £2.2m in a pre-series A funding round, including £500k from the British Business Bank's South West Investment Fund via appointed fund manager The FSE Group. The round includes an option for a further £4.5m in subsequent financing.
The Newquay-based business focuses on converting traditional tablets into stable, ready-to-use liquid medications that remain viable at room temperature. The capital will be deployed to scale operations and expand the workforce, with ten new positions planned over the coming three years to support international growth.
From the founder
"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."
Richard Reavley
Group CEO at Green Park Pharma
Investor perspective
"Green Park Pharma’s robust business model and patented technology present a unique opportunity that we’re excited to be a part of. The secured funding positions the company well for rapid development and market penetration and we look forward to working with them on this journey."
Anna Staevska
Investment Manager, The FSE Group
Use of funds
- 01Scale operations
- 02Grow the team
- 03Expand into international markets
Investors
Categories
About the company
Green Park Pharma
Green Park Pharma formulates liquid alternatives to standard tablet medications.